Phase 2 Pulmonary Hypertension Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• You have signed a written agreement confirming you want to take part in the study.
• You are 18 years old or older when you join the study.
• You have been diagnosed with a type of bile duct cancer that started in the liver (intrahepatic cholangiocarcinoma) that cannot be removed by surgery or has spread to other parts of the body, confirmed by a tissue or cell sample.
• You have already tried one type of treatment for advanced bile duct cancer that stopped working or caused too many side effects — specifically, Cohort A requires prior treatment with gemcitabine/cisplatin plus an immunotherapy drug, and Cohort B requires that same combination plus an additional type of targeted drug (confirm with trial site for which group applies to you).
• At least one area of your cancer can be measured on a CT scan or MRI.
• Your general health and ability to carry out daily activities meets a certain minimum level, as assessed by your doctor using a standard scale (confirm with trial site).
• Your doctor expects you to live for at least 12 weeks.
• Your blood counts, liver function, and kidney function meet specific minimum levels based on recent blood tests (confirm exact values with trial site).
• If you are a woman who could become pregnant, you must have a negative pregnancy test within 7 days before starting the trial.
• You are willing and able to follow all study requirements, including attending appointments, following contraception guidelines, and completing all follow-up visits.

Who may not be able to join:

• You have a significant history of heart disease or have had serious gastrointestinal bleeding within the past 4 weeks.
• You have had a stroke, mini-stroke (TIA), blood clot in a deep vein, or a blood clot in the lungs within the past 6 months (with one specific exception — confirm with trial site).
• You have previously been treated with a procedure called cryoablation (freezing of tumour tissue).
• You have had a tumour-burning procedure (RFA) or surgery to remove tumour tissue within the past 4 weeks.
• You have had radiation therapy within the past 4 weeks.
• You have had major surgery within the past 4 weeks, or you have not yet fully recovered from major surgery.
• You have a second type of cancer, unless it was a common type of skin cancer or a very early-stage cervical condition that has been fully treated.
• You have a weakened immune system, including being HIV-positive.
• You have taken part in another clinical trial or received an experimental treatment within the past 30 days (or longer, depending on the previous drug — confirm with trial site).
• You have certain other health conditions that could affect the safety or results of the study, including: a history of lung scarring (interstitial lung disease); having both hepatitis B and hepatitis C at the same time; known pancreas inflammation; active tuberculosis; any active serious infection requiring treatment; a history of organ or tissue transplant; a condition causing a weakened immune system or use of immune-suppressing medications recently; an active autoimmune disease requiring treatment in the past 3 months (some exceptions apply — confirm with trial site); having received a live vaccine within the past 30 days; or cancer that has spread to the brain or spinal cord (some exceptions apply for people whose brain metastases have been treated and are no longer causing symptoms — confirm with trial site).
• You are currently taking any medication known to interfere with the drugs being used in this trial.
• You are currently receiving any other cancer treatment not specified by this trial.
• You have received any other experimental drug within the past 28 days.
• You have previously been treated with certain specific types of immunotherapy drugs targeting pathways called CD137 (4-1BB) or CTLA-4 (including ipilimumab) (confirm with trial site).
• You are pregnant, breastfeeding, or are a man or woman of childbearing potential who is not using a highly effective form of contraception (acceptable methods include implants, injectable contraceptives, combined oral contraceptives, hormonal intrauterine devices, sexual abstinence, or a vasectomised partner).
• You have a significant history of not following medical instructions, or you are unable to give informed consent reliably.

Important: Always verify eligibility with the trial site directly before applying.